The Latest Menopause Industry Statistics Explained
By 2025, the global menopause treatment market is projected to reach $3.83 billion USD.
The statistic indicates that by the year 2025, the global market for menopause treatment is estimated to grow and reach a value of $3.83 billion USD. This projection suggests a substantial increase in demand for treatments aimed at managing menopausal symptoms worldwide. Factors contributing to this growth could include an aging population, increasing awareness and acceptance of menopause-related issues, advancements in medical research and technology, as well as the development of new treatment options. The forecasted market value of $3.83 billion signifies the potential economic impact and business opportunities within the menopause treatment industry in the near future.
In 2021, the post menopause market, concerning Osteoporosis, Ovarian Cancer and other conditions, globally was estimated about 34.3 billion USD.
The statistic indicates that in 2021, the post menopause market for health conditions like Osteoporosis, Ovarian Cancer, and other related ailments had an estimated value of approximately 34.3 billion USD worldwide. This suggests a significant economic impact of these health issues on the healthcare industry and highlights the growing importance of addressing women’s health needs during the post menopausal stage. The substantial market value also underscores the potential for pharmaceutical companies, healthcare providers, and policymakers to focus on developing effective treatments, raising awareness, and implementing preventive measures to improve the quality of life for postmenopausal women globally.
In North America, the menopause treatment market is expected to reach $930.58 million by 2025.
The statistic indicates that the menopause treatment market in North America is forecasted to grow significantly and reach a value of $930.58 million by the year 2025. This suggests an increasing demand for products and services related to menopause treatment in the region. Factors such as aging population, growing awareness about menopause symptoms and treatments, and advancements in medical technology could contribute to this projected market growth. Stakeholders in the healthcare industry, including pharmaceutical companies, healthcare providers, and policymakers, may need to be prepared for the expanding market and tailor their strategies to meet the evolving needs of menopausal women in North America.
In 2018, estrogen supplement treatment accounted for 55% of the total market share.
The statistic indicates that in 2018, estrogen supplement treatment held a substantial portion of the total market share, accounting for 55%. This suggests that estrogen supplements were a popular choice among consumers seeking such treatments during that year. The high market share implies that estrogen supplements were likely in demand and potentially considered effective by individuals looking to address hormonal imbalances or related health issues. This statistic provides insight into the competitive landscape of the hormone supplement market in 2018, highlighting the prominence of estrogen treatments compared to other options available to consumers.
In 2019, the hormone replacement therapy product segment controlled over 50% of the postmenopausal osteoporosis market share.
The statistic indicates that in 2019, the hormone replacement therapy product segment held a dominant position in the postmenopausal osteoporosis market, accounting for more than half of the market share. This suggests that hormone replacement therapy products were the preferred choice among healthcare providers and patients for managing osteoporosis in postmenopausal women during that time period. The significant market share controlled by this product segment highlights the perceived effectiveness and acceptance of hormone replacement therapy as a treatment option for postmenopausal osteoporosis, potentially due to its positive impact on bone density and fracture risk reduction.
Menopause falls within the top 5 diseases treated by HRT (23%), after hypothyroidism, HIV/AIDS, and infertility.
The statistic indicates that among the diseases for which Hormone Replacement Therapy (HRT) is utilized, menopause falls within the top 5 conditions, accounting for 23% of cases treated with HRT. This places menopause as the fourth most common condition treated by HRT, following hypothyroidism, HIV/AIDS, and infertility. Menopause is a natural stage in a woman’s life marked by the cessation of menstruation and a decline in hormone levels, leading to symptoms such as hot flashes, mood changes, and bone density loss. HRT is often prescribed to alleviate these symptoms by supplementing the declining hormone levels. The statistic highlights the significant role of HRT in managing menopausal symptoms and the prevalent use of this treatment option for women experiencing menopause.
85% of women suffer from menopause symptoms, with the majority preferring non-hormonal treatment as reported by around 30 million.
This statistic suggests that a large proportion of women, specifically 85%, experience symptoms of menopause. This indicates that menopause symptoms are a prevalent issue affecting a substantial number of women, estimated at around 30 million individuals. Additionally, the majority of these women seem to prefer non-hormonal treatments for managing their menopause symptoms. This finding underscores the importance of recognizing and addressing menopause-related symptoms and the preferences of women for non-hormonal treatment options, highlighting the potential need for healthcare providers and policymakers to prioritize the availability and accessibility of such treatments.
Half of women report seeking menopausal advice or treatment, which impacts market demand.
The statistic indicates that a significant proportion of women actively seek advice or treatment for menopausal symptoms, suggesting a high level of interest in addressing menopausal health concerns. This has important implications for the market demand for menopausal products and services, as it suggests a potentially large consumer base looking for effective solutions. Companies in the menopausal health industry should take note of this statistic to tailor their offerings to meet the needs and preferences of women seeking menopausal advice or treatment, in order to capitalize on this market demand effectively and cater to the growing segment of women looking for solutions to manage their menopausal symptoms.
Antidepressants capture 20% of the market for treating hot flashes in 2021.
The statistic “Antidepressants capture 20% of the market for treating hot flashes in 2021” means that among all the treatments available for managing hot flashes, such as hormone therapy, lifestyle changes, and herbal remedies, antidepressants account for a significant portion of usage, specifically 20%. This suggests that a notable proportion of individuals experiencing hot flashes are utilizing antidepressants as a therapeutic option. The statistic provides insight into the popularity and effectiveness of antidepressants in managing hot flashes and highlights their role in the overall market for treating this symptom in 2021.
In 2020, women actively managing their menopause symptoms grew by 50%.
The statistic “In 2020, women actively managing their menopause symptoms grew by 50%” indicates that there was a significant increase in the number of women who were taking steps to actively address and alleviate the symptoms associated with menopause compared to the previous year. This 50% growth suggests that more women recognized the importance of managing their menopause symptoms through various strategies such as lifestyle changes, hormone therapy, or alternative treatments. The increase in women actively managing their menopause symptoms may signify a positive trend towards prioritizing women’s reproductive health and well-being, as well as an increased awareness and acceptance of the challenges that menopause can bring.
47% of women suffering from menopause symptoms prefer natural dietary supplements.
This statistic indicates that nearly half of women experiencing menopause symptoms have a preference for natural dietary supplements as a form of treatment or support. This suggests a significant portion of women in this demographic find value in utilizing natural products over other options, such as prescription medications or lifestyle interventions. The high percentage who prefer natural dietary supplements could be attributed to factors such as perceived effectiveness, fewer side effects, and a desire for a more holistic approach to managing their menopause symptoms. Overall, this statistic highlights the importance of natural supplements in the healthcare choices of menopausal women.
The Asia Pacific region has the fastest growing menopause market due to ageing population.
The statistic suggests that the Asia Pacific region is experiencing a rapid increase in the menopause market as a result of its aging population. As people in this region are living longer and the average age of the population is increasing, there is a growing demand for products and services related to menopause management and care. This trend could be attributed to factors such as improved healthcare leading to longer life expectancy, changing lifestyle habits, and increased awareness about menopause among women in the region. The statistic indicates a significant opportunity for businesses and healthcare providers to cater to the needs of this expanding market segment in the Asia Pacific region.
The proportion of menopausal women seeking treatment has increased from 15% to 70% over the last decade.
The statistic highlighting that the proportion of menopausal women seeking treatment has increased from 15% to 70% over the last decade indicates a significant shift in healthcare-seeking behavior within this demographic group. This substantial change suggests an increasing recognition and acceptance of the importance of seeking appropriate medical care and interventions to manage the symptoms and health implications associated with menopause. The sharp rise from 15% to 70% reflects a clear trend towards proactive and preventative healthcare practices among menopausal women, potentially driven by increased awareness, improved access to healthcare services, and efforts to destigmatize menopause-related concerns. This statistic underscores the evolving nature of healthcare utilization patterns and the growing emphasis on holistic management of women’s health issues, particularly during the menopausal transition.
By 2026, global menopausal hot flashes market is expected to grow $7.77 billion.
The statistic indicates that the global market for menopausal hot flash treatments is projected to experience significant growth, reaching a value of $7.77 billion by the year 2026. This growth suggests an increasing demand for products and services designed to alleviate symptoms associated with menopause such as hot flashes. Factors contributing to this growth may include a growing aging population, increased awareness and diagnosis of menopausal symptoms, and advancements in treatment options. The projected market size highlights the potential for research and development, innovation, and investment in this particular sector of the healthcare industry to address the needs of menopausal individuals experiencing hot flashes.
As of 2021, 910 million women worldwide are of menopausal age, contributing to a growing market.
The statistic ‘As of 2021, 910 million women worldwide are of menopausal age, contributing to a growing market’ indicates the substantial size of the global population of women who have reached or are approaching menopause. This demographic trend has important implications for various industries, particularly the healthcare and pharmaceutical sectors, as a larger number of women seek products and services to manage menopausal symptoms and maintain their health and well-being. This statistic highlights the opportunities for businesses to cater to the needs of menopausal women and develop innovative solutions to address this significant market demand, ranging from hormone replacement therapies to dietary supplements and lifestyle interventions. It will be crucial for companies to understand the unique needs and preferences of this diverse group of women to effectively target this growing market segment.
The percentage of women experiencing premature menopause is between 5% to 10%.
This statistic indicates that the proportion of women who undergo premature menopause falls within a range of 5% to 10%. Premature menopause, also known as premature ovarian insufficiency, refers to the cessation of menstruation and decline in ovarian function before the age of 40. The statement suggests that roughly 5 to 10 out of every 100 women may experience this condition, which can have implications for fertility, hormonal balance, and overall health. Understanding the prevalence of premature menopause is crucial for healthcare providers to offer appropriate support and treatment options to affected individuals within this estimated range.
In Europe, the menopause treatment market will grow at a CAGR of 4.5% from 2021 to 2027.
This statistic suggests that the menopause treatment market in Europe is expected to experience a Compound Annual Growth Rate (CAGR) of 4.5% between the years 2021 and 2027. This indicates a steady and consistent growth trajectory in the market over the specified time period. Factors such as increasing awareness about menopause, advancements in treatment options, and changing demographics could be contributing to this growth. The CAGR serves as a useful metric for assessing the overall growth rate of the market and provides insights into the potential opportunities and trends in the menopause treatment sector in Europe.
Over-the-counter (OTC) solutions account for 65% of the female hormone replacement market.
This statistic indicates that 65% of the market for female hormone replacement products is comprised of over-the-counter (OTC) solutions. This suggests that a significant portion of individuals seeking hormone replacement therapy opt for non-prescription products that can be easily bought without a doctor’s prescription. The popularity of OTC solutions in this market implies a preference for convenience, accessibility, and possibly cost-effectiveness among consumers. It also suggests that there may be a growing trend towards self-management of hormonal imbalances or menopausal symptoms using readily available OTC options, rather than relying solely on prescribed medications.
References
0. – https://www.www.statista.com
1. – https://www.www.heraldtribune.com
2. – https://www.pharmaceuticalmarket.com
3. – https://www.www.mdpi.com
4. – https://www.www.avogel.co.uk
5. – https://www.www.gminsights.com
6. – https://www.www.openslate.com
7. – https://www.www.ncbi.nlm.nih.gov
8. – https://www.www.grandviewresearch.com
9. – https://www.www.bloomberg.com
10. – https://www.womensmidlifehealthjournal.springeropen.com
11. – https://www.www.healthline.com
12. – https://www.www.globenewswire.com
13. – https://www.www.womens-health-concern.org
14. – https://www.www.macleans.ca
